CN114200116A

CN114200116A - Sheath fluid for analyzing urine visible components and preparation method thereof

Info

Publication number: CN114200116A
Application number: CN202111243252.3A
Authority: CN
Inventors: 韩慧麟; 郭建; 王国锋; 吴凌斌
Original assignee: Shanghai Lanqiao Biotechnology Co ltd
Current assignee: Shanghai Lanqiao Biotechnology Co ltd
Priority date: 2021-10-25
Filing date: 2021-10-25
Publication date: 2022-03-18

Abstract

The invention provides a sheath fluid for analyzing urine visible components and a preparation method thereof, wherein the sheath fluid comprises the following steps: solubilizer, surfactant, preservative, osmotic pressure and conductivity regulator, pH regulator and water; the concentration of the solubilizer is 20-40 g/L, and the concentration of the surfactant is 0.3-0.5 g/L; the concentration of the preservative is 0.2-0.4 g/L; the concentration of the osmotic pressure and conductivity regulator is 25-35 g/L; the concentration of the pH regulator is 0.5-1.2 g/L. In the sheath fluid for analyzing urine tangible components, the solubilizer can form hydrogen bond combination with water, so that the solubility of insoluble substances in a reagent or a urine sample is increased, and the solubilizer is used for maintaining the osmotic pressure and potential balance between the sheath fluid for analyzing urine tangible components and the urine sample and improving the stability of each tangible component in the sample; the presence of the surfactant can reduce the friction force of the sheath flow and can inhibit the generation of bubbles; the preservative can increase the stability and antibacterial property of the sheath fluid for analyzing urine visible components.

Description

Sheath fluid for analyzing urine visible components and preparation method thereof

Technical Field

The invention relates to the technical field of biology, in particular to sheath fluid for analyzing urine visible components and a preparation method thereof.

Background

The analysis of urine visible components is a common item in clinical examination, and a relatively advanced urine visible component analyzer is an analyzer adopting a flow cytometry principle, such as a Xisenmeikang UF-500i or UF-1000i urine visible component analyzer. Specifically, this type of analyzer detects urine-forming components by irradiating a sheath flow sample formed in a sheath flow cell after fluorescent staining with a laser beam, and analyzing photoelectric signals converted from forward scattered light, side scattered light, and side fluorescent signals generated from respective particles. Wherein, the sheath flow wrapping can ensure that the particles in the sample are detected in a non-overlapping dispersed mode. Therefore, the sheath fluid is a very important reagent in the instrument, and directly affects the performance and detection result of the instrument.

However, the mainstream urine visible component analyzer in the market is an imported instrument, and the matched sheath liquid is high in price, complex in import procedure and long in transportation time. These problems bring troubles such as high cost and inconvenient use to the majority of medical institutions.

Disclosure of Invention

In order to achieve the above and other related objects, the present invention provides a sheath fluid for analyzing urine visible components, comprising: solubilizer, surfactant, preservative, osmotic pressure and conductivity regulator, pH regulator and water; wherein the content of the first and second substances,

the concentration of the solubilizer is 20-40 g/L, and the concentration of the surfactant is 0.3-0.5 g/L; the concentration of the preservative is 0.2-0.4 g/L; the concentration of the osmotic pressure and conductivity regulator is 25-35 g/L; the concentration of the pH regulator is 0.5-1.2 g/L.

Optionally, the solubilizer comprises at least one of an alkyl alcohol, an alkyl polyol, or a phenyl-substituted alcohol.

Optionally, the surfactant comprises at least one of a nonionic surfactant with a short polyoxyethylene chain or a polyoxyethylene polyoxypropylene block-type nonionic surfactant.

Optionally, the preservative comprises at least one of sorbic acid and salts thereof, benzoic acid and salts thereof, or parabens and salts thereof.

Optionally, the osmolality and conductivity regulator comprises at least one of sodium chloride and sodium sulfate.

Optionally, the pH adjuster comprises hydrochloric acid or sodium hydroxide.

Optionally, the conductivity of the sheath fluid for analyzing the urine sediment component is in a range of 30 to 40mS/cm, the osmotic pressure of the sheath fluid for analyzing the urine sediment component is in a range of 900 to 1100mOsm/kg, and the pH of the sheath fluid for analyzing the urine sediment component is in a range of 7 to 8.

The invention also provides a preparation method of the sheath fluid for analyzing urine visible components, which comprises the following steps:

providing the solubilizing agent, the surfactant, the preservative, the osmolality and conductivity modifier, the pH modifier and the water;

mixing the solubilizer, the surfactant, the preservative and the water to obtain a mixed solution;

adjusting the mixed solution to a preset osmotic pressure and a preset conductivity by using the osmotic pressure and conductivity regulator;

the pH regulator regulates the mixed solution after the osmotic pressure and conductivity regulator is regulated to a preset pH value;

filtering with a microporous filter membrane to obtain sheath fluid for analyzing urine tangible components, wherein the concentration of the solubilizer is 20-40 g/L, the concentration of the surfactant is 0.3-0.5 g/L, the concentration of the preservative is 0.2-0.4 g/L, and the concentration of the osmotic pressure and conductivity regulator is 25-35 g/L; the concentration of the pH value regulator is 0.5-1.2 g/L.

Optionally, the pore diameter of the microporous filter membrane is 0.198-0.202 μm.

Optionally, the preset conductivity is in a range of 30-40 mS/cm, the preset osmotic pressure is in a range of 900-1100 mOsm/kg, and the preset pH value is in a range of 7-8.

As described above, the sheath fluid for analyzing a urine formed component and the method for producing the same according to the present invention have the following advantageous effects: in the sheath fluid for analyzing urine tangible components, the solubilizer can form hydrogen bond with water in the formula, so that the solubility of the insoluble substances in the reagent or the urine sample is increased, the solubility of the surfactant, inorganic salts (such as ammonium phosphate, magnesium phosphate, calcium carbonate and the like), the preservative, urea and other substances is facilitated, and in addition, the solubilizer is used for maintaining the osmotic pressure and potential balance of the sheath fluid for analyzing urine tangible components and the urine sample, so that the stability of each tangible component in the sample is improved; the presence of the surfactant in the formulation can reduce the frictional force of the sheath flow and can suppress the generation of bubbles; the preservative can increase the stability and antibacterial property of the sheath fluid for analyzing urine sediment.

The sheath fluid for analyzing urine visible components has the advantages of simple formula, high accuracy of detection results, good repeatability and stable performance, can achieve the test effect equivalent to that of imported sheath fluid, reduces the production cost and the reagent use cost of each medical institution, and reduces the dependence of each medical institution on imported reagents.

Drawings

Fig. 1 is a flowchart of a method for producing a sheath fluid for analyzing a urine sediment according to the present invention.

FIG. 2 is a diagram of the correlation analysis of the detection result of the concentration of red blood cells in a urine sample by the sheath fluid and the inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer.

FIG. 3 is a graph of correlation between the measurement results of the concentration of leukocytes in a urine sample by using the sheath fluid and the inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer.

FIG. 4 is a diagram of the correlation analysis of the detection result of the concentration of epithelial cells in a urine sample by the sheath fluid and the inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer.

FIG. 5 is a graph of correlation between the detection results of the tube-type concentration in a urine sample by a urine visible component analyzer for sheath fluid and inlet sheath fluid according to example 1 of the present invention.

FIG. 6 is a diagram of the correlation analysis of the detection results of the concentration of bacteria in a urine sample by the sheath fluid and the inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer.

FIG. 7 is a comparison of a erythrocyte scattergram of a sample of the sheath fluid of example 1 of the present invention and an inlet sheath fluid on a urine visible component analyzer, wherein FIG. 7 (a) is a erythrocyte scattergram of the sheath fluid of example 1 of the present invention, and FIG. 7 (b) is a erythrocyte scattergram of the inlet sheath fluid.

FIG. 8 is a comparison of a leukocyte scattergram of a sample of a sheath fluid and an inlet sheath fluid in example 1 of the present invention on a urine visible component analyzer, wherein FIG. 8 (a) is a leukocyte scattergram obtained from the sheath fluid in example 1 of the present invention, and FIG. 8 (b) is a leukocyte scattergram obtained from the inlet sheath fluid.

FIG. 9 is a comparison of a sheath fluid and an inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer showing a sample detection result of epithelial cells and cast scattergrams, wherein FIG. 9 (a) is a graph showing the epithelial cells and cast scattergrams obtained from the sheath fluid of example 1 of the present invention, and FIG. 9 (b) is a graph showing the epithelial cells and cast scattergrams obtained from the inlet sheath fluid.

FIG. 10 is a comparison of a bacterial scattergram of the detection results of a sample of the sheath fluid and the inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer, wherein FIG. 10 (a) is a bacterial scattergram obtained from the sheath fluid of example 1 of the present invention, and FIG. 10 (b) is a bacterial scattergram obtained from the inlet sheath fluid.

FIG. 11 is a comparison of a erythrocyte scattergram of the sheath fluid and the inlet sheath fluid obtained from another sample on a urine visible component analyzer in example 1 of the present invention, wherein FIG. 11 (a) is a erythrocyte scattergram of the sheath fluid of example 1 of the present invention, and FIG. 11 (b) is a erythrocyte scattergram of the inlet sheath fluid.

FIG. 12 is a comparison of a leukocyte scattergram obtained from another sample of the sheath fluid and the inlet sheath fluid of example 1 of the present invention on a urine visible component analyzer, wherein FIG. 12 (a) is a leukocyte scattergram obtained from the sheath fluid of example 1 of the present invention, and FIG. 12 (b) is a leukocyte scattergram obtained from the inlet sheath fluid.

FIG. 13 is a comparison of a sheath fluid and an inlet sheath fluid in example 1 of the present invention on a urine visible components analyzer with respect to epithelial cells and cast scattergrams obtained from another sample, wherein FIG. 13 (a) is a graph of the epithelial cells and cast scattergrams obtained from the sheath fluid in example 1 of the present invention, and FIG. 13 (b) is a graph of the epithelial cells and cast scattergrams obtained from the inlet sheath fluid.

FIG. 14 is a comparison of bacterial scattergrams of the results of measurement of a sheath fluid and an inlet sheath fluid on a urine visible component analyzer for another sample according to example 1 of the present invention, wherein FIG. 14 (a) is a bacterial scattergram obtained from the sheath fluid of example 1 of the present invention, and FIG. 14 (b) is a bacterial scattergram obtained from the inlet sheath fluid.

FIG. 15 is a graph of correlation between the concentration of red blood cells in a urine sample measured by a urine visible component analyzer using sheath fluid and inlet sheath fluid according to example 2 of the present invention.

FIG. 16 is a graph of correlation between the measurement results of the concentration of leukocytes in a urine sample by a urine visible component analyzer for sheath fluid and inlet sheath fluid according to example 2 of the present invention.

FIG. 17 is a graph of correlation between the concentration of epithelial cells in a urine sample measured by a urine visible component analyzer using sheath fluid and inlet sheath fluid according to example 2 of the present invention.

FIG. 18 is a graph of correlation between the detection results of the tube-type concentration of the sheath fluid and the inlet sheath fluid in the urine sample on the urine visible component analyzer according to example 2 of the present invention.

FIG. 19 is a graph of the correlation between the detection results of the concentration of bacteria in a urine sample by a urine visible component analyzer using the sheath fluid and the inlet sheath fluid according to example 2 of the present invention.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

The preferred embodiments in the following description are given by way of example only, and other obvious variations will occur to those skilled in the art. The basic principles of the invention, as defined in the following description, may be applied to other embodiments, variations, modifications, equivalents, and other technical solutions without departing from the spirit and scope of the invention.

The mainstream urine visible component analyzer in the market is an imported instrument, and the matched sheath liquid is high in price, complex in import procedure and long in transportation time. These problems bring troubles such as high cost and inconvenient use to the majority of medical institutions.

Example one

The present invention provides a sheath fluid for analyzing urine visible components, including: solubilizer, surfactant, preservative, osmotic pressure and conductivity regulator, pH regulator and water; wherein the content of the first and second substances,

Specifically, the concentration of the solubilizer can be 25g/L, 30g/L, 35g/L or 38g/L, etc., and the concentration of the surfactant can be 0.35g/L, 0.4g/L or 0.45g/L, etc.; the concentration of the preservative may be 0.25g/L, 0.3g/L, or 0.35g/L, etc.; the concentration of the osmotic pressure and conductivity regulator can be 28g/L, 30g/L or 32g/L and the like; the concentration of the pH adjusting agent may be 0.7g/L, 0.9g/L, or 1.1g/L, and so forth.

Further, the sheath fluid for analyzing a urine sediment component of the present invention may be specifically a sheath fluid for an analyzer that measures a sediment component in urine by a flow cytometry.

In the sheath fluid for analyzing urine tangible components, the solubilizer can form hydrogen bonds with water in the formula, so that the solubility of the insoluble substances in the reagent or the urine sample is increased, the solubility of the substances such as the surfactant, inorganic salts (such as ammonium phosphate, phosphatase, calcium carbonate and the like), the preservative, urea and the like is facilitated, and in addition, the solubilizer is used for maintaining the osmotic pressure and the potential balance of the sheath fluid for analyzing urine tangible components and the urine sample, so that the stability of each tangible component in the sample is improved; the presence of the surfactant in the formulation can reduce the frictional force of the sheath flow and can suppress the generation of bubbles; the preservative can increase the stability and antibacterial property of the sheath fluid for analyzing urine sediment.

By way of example, the solubilizer may include at least one of an alkyl alcohol, an alkyl polyol, or a phenyl-substituted alcohol. Preferably, in this embodiment, the solubilizer may include two or more different species of alkyl alcohol, alkyl polyol, and phenyl-substituted alcohol.

As an example, the surfactant may include at least one of a nonionic surfactant with a short polyoxyethylene chain or a polyoxyethylene polyoxypropylene block type nonionic surfactant.

As an example, the preservative may include at least one of sorbic acid and its salts, benzoic acid and its salts, or parabens and their salts.

As an example, the osmolality and conductivity regulator may include at least one of sodium chloride and sodium sulfate. Preferably, in this embodiment, the osmotic pressure and conductivity regulator includes two kinds, that is, the osmotic pressure and conductivity regulator includes sodium chloride and sodium sulfate.

As an example, the pH adjuster may include hydrochloric acid or sodium hydroxide.

For example, the conductivity of the sheath fluid for analyzing a urine sediment component may be in a range of 30 to 40mS/cm (millisiemens per centimeter), the osmotic pressure of the sheath fluid for analyzing a urine sediment component may be in a range of 900 to 1100mOsm/kg (milliosmol per kilogram), and the pH of the sheath fluid for analyzing a urine sediment component may be in a range of 7 to 8.

Specifically, the conductivity of the sheath fluid for analyzing urine sediment concentration may be 32mS/cm, 34mS/cm, 36mS/cm, 38mS/cm, or the like; the osmotic pressure of the sheath fluid for analyzing urine sediment may be 950mOsm/kg, 1000mOsm/kg, 1050mOsm/kg, or the like; the pH of the sheath fluid for urine sediment analysis may be 7.2, 7.4, 7.6, or 7.8, or the like.

Example two

Referring to fig. 1, the present embodiment further provides a method for preparing a sheath fluid for analyzing urine visible components, including:

s1, providing the solubilizer, the surfactant, the preservative, the osmotic pressure and conductivity regulator, the pH regulator and the water;

s2, mixing the solubilizer, the surfactant, the preservative and the water to obtain a mixed solution;

s3, adjusting the mixed solution to a preset osmotic pressure and a preset conductivity by using the osmotic pressure and conductivity regulator;

s4, adjusting the mixed solution after the osmotic pressure and conductivity regulator is adjusted to a preset pH value by the pH regulator;

s5, filtering the solution by using a microporous filter membrane to obtain sheath liquid for analyzing urine visible components, wherein the concentration of the solubilizer is 20-40 g/L, the concentration of the surfactant is 0.3-0.5 g/L, the concentration of the preservative is 0.2-0.4 g/L, and the concentration of the osmotic pressure and conductivity regulator is 25-35 g/L; the concentration of the pH value regulator is 0.5-1.2 g/L.

Specifically, in step S5, the concentration of the solubilizer can be 25g/L, 30g/L, 35g/L, 38g/L or the like, and the concentration of the surfactant can be 0.35g/L, 0.4g/L, 0.45g/L or the like; the concentration of the preservative may be 0.25g/L, 0.3g/L, or 0.35g/L, etc.; the concentration of the osmotic pressure and conductivity regulator can be 28g/L, 30g/L or 32g/L and the like; the concentration of the pH regulator can be 0.5-1.2 g/L.

As an example, the pore diameter of the microporous filter membrane can be 0.198-0.202 μm.

Specifically, the pore size of the microfiltration membrane may be 0.199. mu.m, 0.2. mu.m, 0.201. mu.m, or the like.

For example, in step S3, the preset conductivity may be in a range of 30 to 40mS/cm, and the preset osmolality may be in a range of 900 to 1100 mOsm/kg; in step S4, the preset pH value may be 7 to 8.

Specifically, in step S3, the preset conductivity may be 32mS/cm, 34mS/cm, 36mS/cm, or 38mS/cm, etc.; the preset osmotic pressure may be 950mOsm/kg, 1000mOsm/kg or 1050mOsm/kg, etc.; in step S4, the preset pH value may be 7.2, 7.4, 7.6, or 7.8, and so on.

The terms used in the present invention generally have the meanings commonly understood by those of ordinary skill in the art, unless otherwise indicated.

The purity of the reagents used in the examples of the present invention was analytical grade.

The sheath liquid for analyzing urine formed components is suitable for a Xisenmeikang UF-500i or UF-1000i urine formed component analysis system.

In order to facilitate understanding of the technical solutions of the present application, different examples are specifically set forth below.

Example 1

A sheath fluid for analyzing urine visible components has a formula shown in Table 1.

Table 1 inventive example 1 sheath fluid formulation

The preparation method comprises the following steps: the above reagents were mixed to obtain a mixed solution, and then the pH was adjusted to 7.8 with HCl, followed by filtration through a 0.2 μm microporous membrane to obtain the sheath fluid of example 1, which had a conductivity of 32mS/cm and an osmotic pressure of 1050 mOsm/kg.

The sheath fluid of the invention of example 1 was tested on a Hesimecon UF-1000i urine visible constituents analyzer, with 10 different urine samples. The correlation analysis was performed between the obtained results and the original sheath fluid (i.e., the inlet sheath fluid in FIGS. 2 to 6), and the obtained results are shown in FIGS. 2 to 6. As can be seen from the results, the sheath fluid and the original sheath fluid of the invention have high correlation with the detection results of concentration parameters of Red Blood Cells (RBC), White Blood Cells (WBC), Epithelial Cells (EC), CAST (CAST) and Bacteria (BACT) in urine, and the sheath fluid of the invention can achieve the test effect equivalent to the original sheath fluid.

Fig. 7-14 are graphs comparing scattergrams of 2 urine samples measured on a schirmen UF-1000i urine visible constituent analyzer using the sheath fluid of example 1 and the sheath fluid as received (i.e., the inlet sheath fluid of fig. 7-14). As a result, the RBC scattergram, the WBC scattergram, the EC/CAST scattergram and the BACT scattergram of the sheath fluid can achieve the test effect equivalent to that of the original sheath fluid.

Further, the sheath fluid of the present invention of example 1 was continuously subjected to 10 tests on factory quality control products (high value and low value) using a Hismex UF-1000i urine visible component analyzer, and the results are shown in Table 3. The average value is compared with the target value of the quality control product, and the calculated deviation is within the reference range, so that the sheath fluid detection result has high accuracy. The coefficient of variation CV% calculated for the 10 results is shown in Table 2, which is within the coefficient of variation required by the manufacturer, so that the sheath fluid detection results of the invention meet the instrument repeatability requirements.

Table 2 example 1 of the present invention the sheath fluid was used in a shisenmeikang UF-1000i urine visible component analyzer to examine the quality control of the plant (accuracy and reproducibility examination results)

The sheath fluid of the invention of example 1 was left for 6 months and 12 months and then subjected to continuous 10-time testing on the quality control product of the original factory, and the apparatus was a Hismex UF-1000i urine visible component analyzer. The results are shown in tables 3 and 4. The average value of the test is compared with the target value of the quality control product, the calculation deviation is within the reference range, and the calculated variation coefficient is within the range required by the original factory, so that the sheath fluid has good stability after being placed for 6 months and 12 months.

Table 3 test results (stability test results) of quality control of the plant on a xisenmeikang UF-1000i urine visible component analyzer after 6 months of standing of the sheath fluid of example 1 of the present invention

Table 4 test results (stability test results) of quality control of the plant on a xisenmeikang UF-1000i urine visible component analyzer after 12 months of standing of sheath fluid of example 1 of the present invention

Example 2

A sheath fluid for analyzing urine visible components has a formulation shown in Table 5.

Composition (I)	Content (wt.)
		Ethylene glycol phenyl ether	25g/L
Polyethylene glycol glyceryl monostearate	0.4g/L
		Sodium methyl p-hydroxybenzoate	0.3g/L
Sodium chloride	15g/L
		Sodium sulfate	15g/L
Pure water	1L

TABLE 5 sheath fluid compounding ratio of inventive example 2

The preparation method comprises the following steps: the above reagents were mixed to obtain a mixed solution, and then the pH was adjusted to 7.5 with HCl, followed by filtration through a 0.2 μm microporous membrane to obtain the sheath fluid of example 2, which had a conductivity of 35mS/cm and an osmotic pressure of 980 mOsm/kg.

Example 2 the inventive sheath fluid was tested on a xisenmeikang UF-1000i urine visible component analyzer, with 10 different urine samples. The correlation analysis between the obtained results and the original sheath fluid is performed, and the obtained results are shown in FIGS. 15 to 19. As can be seen from the results, the sheath fluid and the original sheath fluid of the invention have high correlation with the detection results of parameters of Red Blood Cells (RBC), White Blood Cells (WBC), Epithelial Cells (EC), CAST (CAST) and Bacteria (BACT) in urine, and the sheath fluid of the invention can achieve the test effect equivalent to the original sheath fluid at the inlet of the original package.

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.

Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.

Claims

1. A sheath fluid for analyzing urine sediment, comprising: solubilizer, surfactant, preservative, osmotic pressure and conductivity regulator, pH regulator and water; wherein the content of the first and second substances,

2. The sheath fluid for analyzing a urinary sediment according to claim 1, characterized in that: the solubilizer comprises at least one of alkyl alcohol, alkyl polyalcohol or phenyl substituted alcohol.

3. The sheath fluid for analyzing a urinary sediment according to claim 1, characterized in that: the surfactant includes at least one of a nonionic surfactant with a short polyoxyethylene chain or a polyoxyethylene polyoxypropylene block-type nonionic surfactant.

4. The sheath fluid for analyzing a urinary sediment according to claim 1, characterized in that: the preservative comprises at least one of sorbic acid and salts thereof, benzoic acid and salts thereof, or parabens and salts thereof.

5. The sheath fluid for analyzing a urinary sediment according to claim 1, characterized in that: the osmotic pressure and conductivity regulator includes at least one of sodium chloride and sodium sulfate.

6. The sheath fluid for analyzing a urinary sediment according to claim 1, characterized in that: the pH regulator comprises hydrochloric acid or sodium hydroxide.

7. The sheath fluid for analyzing a urinary sediment concentration according to any one of claims 1 to 6, characterized in that: the conductivity range of the sheath fluid for analyzing the urine sediment component is 30-40 mS/cm, the osmotic pressure range of the sheath fluid for analyzing the urine sediment component is 900-1100 mOsm/kg, and the pH value of the sheath fluid for analyzing the urine sediment component is 7-8.

8. A method for preparing a sheath fluid for analyzing urine visible components, which is characterized by comprising the following steps: the method comprises the following steps:

9. The method for producing a sheath fluid for analyzing a urine sediment according to claim 8, further comprising: the aperture of the microporous filter membrane is 0.198-0.202 μm.

10. The method for producing a sheath fluid for analyzing a urine sediment according to claim 8 or 9, further comprising: the range of the preset conductivity is 30-40 mS/cm, the range of the preset osmotic pressure is 900-1100 mOsm/kg, and the preset pH value is 7-8.